Diamondback 360

Cardiovascular Systems, Inc. (CSI) is devoted to developing and commercializing innovative solutions for treating peripheral and coronary artery disease. Our primary focus is helping physicians conquer even the most difficult disease states, including calcium, given the complications it presents for the millions who suffer from peripheral artery disease (PAD) and coronary artery disease (CAD). CSI is committed to clinical rigor, constant innovation, and a defining drive to set the standard in safe and effective medical devices to help improve patient outcomes.

We have developed patented orbital atherectomy systems (OAS) technology for both peripheral and coronary commercial applications.

Our peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a broad range of plaque types in leg arteries both above and below the knee and address many of the limitations associated with other treatment alternatives.

Our coronary product is a catheter-based platform designed to facilitate stent delivery in patients with coronary artery disease (CAD) who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to de novo, severely calcified coronary artery lesions. The Coronary OAS design is similar to technology used in our Peripheral OAS, customized specifically for the coronary application.